These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 179171)

  • 1. Suppression of mixed lymphocyte response in mice bearing primary tumors induced by murine sarcoma virus.
    Fernbach BR; Kirchner H; Bonnard GD; Herberman RB
    Transplantation; 1976 May; 21(5):381-6. PubMed ID: 179171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice.
    Kirchner H; Muchmore AV; Chused TM; Holden HT; Herberman RB
    J Immunol; 1975 Jan; 114(1 Pt 1):206-10. PubMed ID: 122986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus.
    Kirchner H; Chused TM; Herberman RB; Holden HT; Lavrin DH
    J Exp Med; 1974 Jun; 139(6):1473-87. PubMed ID: 4598016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity against Moloney sarcoma virus in H-2Db mutant bm14 mice. Unimpaired tumor immunity despite absence of a virus-specific cytotoxic T-cell response.
    Stukart MJ; Boes J; Melief CJ
    Int J Cancer; 1984 Feb; 33(2):265-9. PubMed ID: 6319305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
    Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of the immune response in tumor-bearing mice. III. Induction of functionally suppressive antigen-driven macrophages.
    Bluestone JA; Lopez C
    Cancer Invest; 1983; 1(1):5-13. PubMed ID: 6199094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor inhibiting capacity of spleen and lymph node cells from mice with murine sarcoma virus (MSV-M)-induced tumors.
    Weiland E; Mussgay M
    Z Immunitatsforsch Exp Klin Immunol; 1975 Nov; 150(5):414-23. PubMed ID: 181922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of mouse migration inhibitory factor (MIF) production form MSV-immune lymphocytes by soluble tumor-associated antigen: requirement for histocompatible macrophages.
    Landolfo S; Herberman RB; Holden HT
    J Immunol; 1977 Apr; 118(4):1244-8. PubMed ID: 191532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine sarcoma virus pseudotypes used as immunogens against viral and chemical oncogenesis.
    Basombrío MA; Mayer AM; Pasqualini CD
    Cancer Res; 1977 Jun; 37(6):1768-76. PubMed ID: 192461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulatory effect of immunization on tumor induction by Moloney murine sarcoma virus.
    Murasko DM; Prehn RT
    J Natl Cancer Inst; 1978 Nov; 61(5):1323-7. PubMed ID: 213613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of T cell-mediated immunity by tumor cells: immunogenicity versus immunosuppression and preliminary characterization of the suppressive factors.
    Ting CC; Rodrigues D; Ting RC; Wivel N; Collins MJ
    Int J Cancer; 1979 Nov; 24(5):644-55. PubMed ID: 160896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exclusive involvement of H-2Db or H-2Kd product in the interaction between T-killer lymphocytes and syngeneic H-2b or H-2d viral lymphomas.
    Gomard E; Duprez V; Reme T; Colombani MJ; Levy JP
    J Exp Med; 1977 Oct; 146(4):909-22. PubMed ID: 197198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary cell-mediated cytotoxic response to syngeneic mouse tumor challenge.
    Holden HT; Kirchner H; Herberman RB
    J Immunol; 1975 Aug; 115(2):327-31. PubMed ID: 168259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
    Plata F; Jongeneel V; Cerottini JC; Brunner KT
    Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The murine sarcoma virus-induced tumor: exception or general model in tumor immunology?
    Levy JP; Leclerc JC
    Adv Cancer Res; 1977; 24():1-66. PubMed ID: 66859
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of in vitro growth of lymphoma cells by macrophages from tumor-bearing mice.
    Kirchner H; Holden HT; Herberman RB
    J Natl Cancer Inst; 1975 Oct; 55(4):971-5. PubMed ID: 171434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro studies on effector cell diversity in the cellular immune response to murine sarcoma virus (MSV)-induced tumors in mice.
    Plata F; Gomard E; Leclerc JC; Levy JP
    J Immunol; 1974 Apr; 112(4):1477-87. PubMed ID: 4360862
    [No Abstract]   [Full Text] [Related]  

  • 18. Suppression of the immune response in tumor-bearing mice. II. Characterization of adherent suppressor cells.
    Bluestone JA; Lopez C
    J Natl Cancer Inst; 1979 Nov; 63(5):1221-7. PubMed ID: 228106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H-2 region product as determinant in immune cytolysis of syngeneic tumour cells by anti-MSV T lymphocytes.
    Gomard E; Duprez V; Henin Y; Levy JP
    Nature; 1976 Apr; 260(5553):707-9. PubMed ID: 177884
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization to effector lymphocytes associated with immunity to murine sarcoma virus (MSV)-induced tumors. II. Repeated stimulation and proliferation in vitro of specific cytolytic T lymphocytes.
    Plata F; Jongeneel CV
    J Immunol; 1977 Aug; 119(2):623-9. PubMed ID: 196025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.